Geratherm Medical AG (GB:0EL9)
LSE:0EL9
0EL9 Stock Chart & Stats
€2.84
€0.08(2.35%)
At close: 4:00 PM EST
€2.84
€0.08(2.35%)
Day’s Range― - ―
52-Week Range€2.64 - €7.76
Previous CloseN/A
Volume52.00
Average Volume (3M)23.00
Market Cap
€15.03M
Enterprise Value€10.13M
Total Cash (Recent Filing)€9.61M
Total Debt (Recent Filing)€2.62M
Price to Earnings (P/E)16.4
Beta0.29
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding5,444,998
10 Day Avg. Volume26
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)0.90
Price to Sales (P/S)0.92
P/FCF Ratio15.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€16.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA very low debt-to-equity ratio indicates conservative leverage and a solid equity base. That durability supports funding operations, R&D or tender participation without raising excessive debt, giving the business financial flexibility to navigate healthcare cycles over months to years.
Improving Cash GenerationRising free cash flow and a high operating cash flow-to-net income ratio show stronger cash conversion versus earnings. This improves the company’s ability to self-fund maintenance capex, service contracts and selective investment, enhancing resilience and strategic optionality.
Defensible Product & Market MixA diversified device portfolio across hospital, home and outpatient channels plus recurring service and tender revenue creates multiple durable revenue streams. That mix supports steady demand and mitigates reliance on any single channel or short-term market fluctuation.
Bears Say
Declining Revenue GrowthMaterial year-over-year revenue contraction signals persistent demand or market-share weakness. Sustained top-line decline makes it harder to leverage fixed costs, constrains reinvestment capacity and raises the bar for management to restore organic growth over the medium term.
Compressing Gross MarginsA falling gross margin implies pricing pressure or rising input costs and erodes operating leverage. Over months this compresses operating profit potential and increases reliance on volume recovery or cost restructuring to sustain net margins and fund strategic initiatives.
Suboptimal FCF ConversionFCF lagging net income means earnings are not fully translating into spendable cash, limiting internal funding for growth, dividends or debt repayment. This structural conversion gap could constrain capital allocation flexibility if persistent over coming quarters.
0EL9 FAQ
What was Geratherm Medical AG’s price range in the past 12 months?
Geratherm Medical AG lowest share price was €2.64 and its highest was €7.76 in the past 12 months.
What is Geratherm Medical AG’s market cap?
Geratherm Medical AG’s market cap is €15.03M.
When is Geratherm Medical AG’s upcoming earnings report date?
Geratherm Medical AG’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.
How were Geratherm Medical AG’s earnings last quarter?
Geratherm Medical AG released its earnings results on Jun 11, 2026. The company reported -€0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.12.
Is Geratherm Medical AG overvalued?
According to Wall Street analysts Geratherm Medical AG’s price is currently Overvalued.
Does Geratherm Medical AG pay dividends?
Geratherm Medical AG does not currently pay dividends.
What is Geratherm Medical AG’s EPS estimate?
Geratherm Medical AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Geratherm Medical AG have?
Geratherm Medical AG has 5,444,998 shares outstanding.
What happened to Geratherm Medical AG’s price movement after its last earnings report?
Geratherm Medical AG reported an EPS of -€0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Geratherm Medical AG?
Currently, no hedge funds are holding shares in GB:0EL9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geratherm Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Geratherm Medical AG
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range of items including clinical thermometers, blood pressure monitors, and various self-test diagnostic products designed for women, such as pregnancy tests, chlamydia screens, urinary tract infection indicators, diverse ovulation solutions, and pH tests. Its Respiratory segment is dedicated to the development and production of equipment primarily for diagnosing pulmonary and cardiopulmonary function. Under the LMT brand, the Medical Warming Systems division manufactures MRI-compatible incubators for premature and newborn infants. The Cardio/Stroke segment provides analytical products aimed at assessing stroke risk by detecting atrial fibrillation. The company markets its healthcare solutions via pharmacies, hospitals, and clinics, and successfully exports its merchandise to approximately 60 nations worldwide. Established in 1990, Geratherm Medical AG's headquarters are situated in Geschwenda, Germany.